ADA: Safety Data Offset Efficacy for Survodutide
The drug cut weight and liver fat, but gastrointestinal side effects drove a 19% dropout rate versus 2.9% on placebo.
- Shares of weight loss drug maker Zealand Pharma plummeted as much as 26% on Monday after data revealed that 19% of patients in its survodutide trial dropped out due to gastrointestinal events.
- Boehringer Ingelheim and Zealand presented results from the SYNCHRONIZE-1 and SYNCHRONIZE-MASLD trials at the American Diabetes Association meeting over the weekend, confirming the drug met key late-stage targets.
- In SYNCHRONIZE-MASLD, 84.2% of survodutide-treated patients achieved a 30% or greater reduction in liver fat, while 61% saw liver fat reduce to normal levels, demonstrating metabolic health benefits beyond weight loss.
- Barclays analysts said "Safety/tolerability remains the key issue," while Citi noted the 19% discontinuation rate sits well above levels seen with rival drug Wegovy, raising commercial viability concerns.
- Researchers attributed the high toxicity to a rigid dose-escalation regimen that lacked flexibility to adjust dosing when side effects appeared, though Boehringer and Zealand have not disclosed filing plans and future LIVERAGE trials are not due until 2029.
11 Articles
11 Articles
The market for obesity drugs will grow to more than $100 billion by the end of the 2030s. The competition is correspondingly tough. Boehringer Ingelheim, a pharmaceutical company, now provides data for a medium that is not quite clear.
BT
Zealand Pharma plunged 22 percent Monday morning on news from the weekend's diabetes conference.
Weight loss drug maker sinks 23% after new safety data spooks investors
In this article NVO ROP-CH AZN-GB .STOXX Follow your favorite stocksCREATE FREE ACCOUNT Shares of weight loss drug maker Zealand Pharma plummeted as much as 23% on Monday after new data on its experimental medicine raised concerns over its potential side effects. The Danish drugmaker said that while its drug survodutide, which it has licensed to privately-held Boehringer Ingelheim, met its key targets in a late-stage study, 19% of patients drop…
Coverage Details
Bias Distribution
- 50% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
